BridgeBio (BBIO) Q2 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Globe and Mail, The
Chief Financial Officer and President — Thomas Trimarchi Chief Commercial Officer — Matthew Outten Senior Vice President, Strategic Finance — Chinmay Shukla Leader, ADH1 Phase III Program — Ananth Sridhar Leader, LGMD2I Phase III Program — Christine Siu Leader, Achondroplasia Phase III Program — Justin To Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Total Revenue -- $110.6 million was reported, driven by $71.5 million in U.S. net product revenue for Attruby, $1.6 million in ex-U.S. BEYONTTRA royalties, and $35.3 million in license and service revenue, including a $30 million milestone from Alexion following BEYONTTRA pricing approval in Japan. Attruby Prescriptions -- 3,751 unique patient prescriptions were tracked, with 1,074 unique prescribers and over 30% quarter-over-quarter growth in weekly prescription volume. Attruby Net Product Revenue -- $71.5 million was generated, an increase of 100% sequentially from Q1 2025. New Patient Adds
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (BBIO) had its price target raised by Truist Financial Corporation from $95.00 to $102.00. They now have a "buy" rating on the stock.MarketBeat
- BridgeBio (BBIO) Q2 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (BBIO) had its "outperform" rating reaffirmed by Mizuho. They now have a $106.00 price target on the stock.MarketBeat
- BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White [Yahoo! Finance]Yahoo! Finance
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 2/24/26 - Miss
BBIO
Sec Filings
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form ARS
- 4/24/26 - Form DEF
- BBIO's page on the SEC website